Mr. Sackett is an entrepreneurial leader with over a decade of experience building and scaling mission-driven organizations, with a focus on translating cutting-edge research for the benefit of patients. Mr. Sackett was most recently at MyoKardia / BMS, where he joined in 2015 prior to MyoKardia’s IPO, holding roles of increasing responsibility, culminating in his position as Head of Business Development and Head of Corporate Strategy at the time of MyoKardia’s sale to Bristol Myers Squibb for $13.1 billion. In this role, he led various activities including all licensing, partnering and M&A, corporate strategy and competitive intelligence, and additionally, at various points during his time at MyoKardia, led and served as a key contributor to the portfolio strategy, investor relations, corporate communications, capital markets and finance functions. He also previously held operating, investing or finance roles at Silk Road Medical, American Infrastructure Funds, RBC Capital Markets, and at Valero. Wayne holds an MBA from Harvard Business School and a BS, with honors, in chemical engineering from the University of California, Berkeley.